- Home
- STKE vs MIRA Comparison
STKE vs MIRA Comparison
Compare STKE & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STKE | MIRA |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 43.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | STKE | MIRA |
|---|---|---|
| Price | $1.60 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 185.8K | 127.7K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $552.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.90 |
| 52 Week High | $7.75 | $2.45 |
Technical Indicators
Market Signals| Indicator | STKE | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 43.96 |
| Support Level | $1.50 | $0.99 |
| Resistance Level | $1.65 | $1.24 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 89.17 | 10.71 |
Price Performance
Historical ComparisonAbout STKE Sol Strategies Inc.
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.